NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Nicardipine Hydrochloride In 0.9% Sodium Chloride patents expire, and when can generic versions of Nicardipine Hydrochloride In 0.9% Sodium Chloride launch?
Nicardipine Hydrochloride In 0.9% Sodium Chloride is a drug marketed by Cipla and Hikma Intl Pharms and is included in two NDAs.
The generic ingredient in NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nicardipine Hydrochloride In 0.9% Sodium Chloride
A generic version of NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE was approved as nicardipine hydrochloride by ANI PHARMS on October 28th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
- What are the global sales for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
- What is Average Wholesale Price for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
Summary for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 4 |
| Clinical Trials: | 53 |
| DailyMed Link: | NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at DailyMed |
Recent Clinical Trials for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Boston Medical Center | Phase 4 |
| University of Illinois at Chicago | Early Phase 1 |
| Nanjing First Hospital, Nanjing Medical University | N/A |
See all NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE clinical trials
Pharmacology for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
US Patents and Regulatory Information for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 215592-001 | Sep 24, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma Intl Pharms | NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 022276-003 | Apr 7, 2016 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cipla | NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 215592-002 | Sep 24, 2024 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Hikma Intl Pharms | NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE | nicardipine hydrochloride | INJECTABLE;INTRAVENOUS | 022276-002 | Apr 7, 2016 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
